ATE381569T1 - Epothilonderivate - Google Patents
EpothilonderivateInfo
- Publication number
- ATE381569T1 ATE381569T1 AT03747872T AT03747872T ATE381569T1 AT E381569 T1 ATE381569 T1 AT E381569T1 AT 03747872 T AT03747872 T AT 03747872T AT 03747872 T AT03747872 T AT 03747872T AT E381569 T1 ATE381569 T1 AT E381569T1
- Authority
- AT
- Austria
- Prior art keywords
- epothilone
- analogs
- epothilone derivatives
- epoxide
- potent
- Prior art date
Links
- 150000003883 epothilone derivatives Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 cyclopropane epothilone Chemical class 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- 150000003885 epothilone B derivatives Chemical class 0.000 abstract 1
- 150000002118 epoxides Chemical class 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Silicon Polymers (AREA)
- Dental Preparations (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40053502P | 2002-08-02 | 2002-08-02 | |
| US48093303P | 2003-06-24 | 2003-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE381569T1 true ATE381569T1 (de) | 2008-01-15 |
Family
ID=31720540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03747872T ATE381569T1 (de) | 2002-08-02 | 2003-08-01 | Epothilonderivate |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7169930B2 (de) |
| EP (1) | EP1546152B1 (de) |
| JP (1) | JP4276171B2 (de) |
| CN (1) | CN100439374C (de) |
| AT (1) | ATE381569T1 (de) |
| AU (1) | AU2003266961A1 (de) |
| BR (1) | BR0313198A (de) |
| CA (1) | CA2494259A1 (de) |
| DE (1) | DE60318224T2 (de) |
| ES (1) | ES2297189T3 (de) |
| PT (1) | PT1546152E (de) |
| WO (1) | WO2004014919A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP2186811A1 (de) | 2002-08-23 | 2010-05-19 | Sloan-Kettering Institute For Cancer Research | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2004268377B2 (en) * | 2003-09-02 | 2008-06-26 | Novartis Ag | Cancer treatment with epothilones |
| GB0405898D0 (en) | 2004-03-16 | 2004-04-21 | Novartis Ag | Organic compounds |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| US7754850B2 (en) | 2005-02-11 | 2010-07-13 | University Of Southern California | Chimeric disintegrin domain |
| JP2009516753A (ja) * | 2005-11-22 | 2009-04-23 | ザ スクリップス リサーチ インスティテュート | 高度に効力を持つエポチロンの化学合成 |
| EP2029156A4 (de) * | 2006-05-01 | 2010-07-21 | Univ Southern California | Kombinationstherapie zur krebsbehandlung |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| US20110300150A1 (en) | 2010-05-18 | 2011-12-08 | Scott Eliasof | Compositions and methods for treatment of autoimmune and other disease |
| EP2793947B1 (de) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatische konjugation von polypeptiden |
| US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
| EP3564259A3 (de) | 2012-11-09 | 2020-02-12 | Innate Pharma | Kennungen für tgase-vermittelte konjugation |
| US10611824B2 (en) | 2013-03-15 | 2020-04-07 | Innate Pharma | Solid phase TGase-mediated conjugation of antibodies |
| EP3010547B1 (de) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatische konjugation von polypeptiden |
| CN105517577A (zh) | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| ES2315399T3 (es) * | 2001-08-23 | 2009-04-01 | Novartis Ag | Analogos de epotilona ciclobutilo y ciclopropilo. |
| WO2003026744A1 (en) * | 2001-09-25 | 2003-04-03 | Alcon, Inc. | The use of epothilones and analogs in conjunction with ophthalmic surgery |
-
2003
- 2003-08-01 BR BR0313198-0A patent/BR0313198A/pt not_active IP Right Cessation
- 2003-08-01 AU AU2003266961A patent/AU2003266961A1/en not_active Abandoned
- 2003-08-01 DE DE60318224T patent/DE60318224T2/de not_active Expired - Fee Related
- 2003-08-01 CA CA002494259A patent/CA2494259A1/en not_active Abandoned
- 2003-08-01 WO PCT/EP2003/008554 patent/WO2004014919A1/de not_active Ceased
- 2003-08-01 CN CNB038186446A patent/CN100439374C/zh not_active Expired - Fee Related
- 2003-08-01 EP EP03747872A patent/EP1546152B1/de not_active Expired - Lifetime
- 2003-08-01 PT PT03747872T patent/PT1546152E/pt unknown
- 2003-08-01 ES ES03747872T patent/ES2297189T3/es not_active Expired - Lifetime
- 2003-08-01 AT AT03747872T patent/ATE381569T1/de not_active IP Right Cessation
- 2003-08-01 JP JP2004526852A patent/JP4276171B2/ja not_active Expired - Fee Related
- 2003-08-04 US US10/634,537 patent/US7169930B2/en not_active Expired - Fee Related
-
2006
- 2006-08-28 US US11/511,610 patent/US20060293527A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313198A (pt) | 2005-07-12 |
| CN1675220A (zh) | 2005-09-28 |
| US20040072870A1 (en) | 2004-04-15 |
| AU2003266961A1 (en) | 2004-02-25 |
| CN100439374C (zh) | 2008-12-03 |
| ES2297189T3 (es) | 2008-05-01 |
| EP1546152B1 (de) | 2007-12-19 |
| US7169930B2 (en) | 2007-01-30 |
| CA2494259A1 (en) | 2004-02-19 |
| DE60318224D1 (de) | 2008-01-31 |
| EP1546152A1 (de) | 2005-06-29 |
| PT1546152E (pt) | 2008-03-12 |
| JP4276171B2 (ja) | 2009-06-10 |
| DE60318224T2 (de) | 2009-01-29 |
| JP2006503814A (ja) | 2006-02-02 |
| WO2004014919A1 (de) | 2004-02-19 |
| US20060293527A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE381569T1 (de) | Epothilonderivate | |
| ECSP055524A (es) | Derivados de indolin-fenilsufonamida | |
| CR20130309A (es) | Derivados de biciclo [3,2,1] octilamida y sus usos | |
| HN2004000146A (es) | Dihidroquinazolinas sustituidas | |
| CL2008003063A1 (es) | Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras. | |
| MX374526B (es) | Inhibidores de nadph oxidasa 4. | |
| EA200601107A1 (ru) | Композиции, получаемые из морских растений, для обеспечения питания для старческой и поврежденной окружающей средой кожи | |
| UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
| ECSP055626A (es) | Nuevos conjugados de efectores, procedimientos para su preparación y su uso farmacéutico | |
| CY1116269T1 (el) | Χρηση μιας πρωτεϊνης απο λουπινο | |
| FI20021184A7 (fi) | Lignaanivalmisteita | |
| ATE469575T1 (de) | Ringsatz | |
| UY28313A1 (es) | Nonadepsipeptidos acilados | |
| PA8694701A1 (es) | Cultivar de arroz denominado 'cl131' | |
| HN2010000128A (es) | Imidazoles sustituidos con heterociclilamida | |
| ECSP066693A (es) | Derivados de bencimidazol | |
| DOP2006000280A (es) | Nuevos derivados de furopirimidina acíclicos sustituidos y su uso | |
| UY29358A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
| EA200500326A1 (ru) | Применение ферментированного экстракта проростков пшеницы в качестве противовоспалительного агента | |
| CR8009A (es) | Compuestos benzo[1,2,5] tiadiazoles | |
| UY29040A1 (es) | Procedimiento de amino-tropano, su preparación y aplicación en terapéutica | |
| UY27628A1 (es) | "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco" | |
| DE60332849D1 (de) | Samen-assoziierte promotorsequenzen | |
| TR2022013893U4 (tr) | Deği̇şti̇ri̇lebi̇li̇r tasarimli demonte yüzük | |
| ITPC20050061A1 (it) | Impianto per la produzione del correttivo agricolo denominato "gesso di defecazione" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1546152 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |